Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks biotech giant Amgen blew Wall Street away when it released third quarter earnings on Oct. 28. Amgen beat analyst revenue estimates by posting revenues of $5.72 billion, compared to the $5.23 billion analysts expected. That’s up from about $5 billion during last year’s third quarter. Net income increased to $1.86 billion during the Read More →
Sientra CEO Hani Zeini said in a conference call on Oct. 28 that he will not speculate about the company’s future. Zeini dodged questions better than a Brooklyn Dodger dodges street cars during the call with investors, analysts and reporters to update all parties about implants contaminated by Sientra’s manufacturer. Sientra shares nosedived on Sept. Read More →
The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →
Goleta breast implant developer Sientra said there had been a fire at the factory of its manufacturer in Brazil, the company announced on Oct. 23. Sientra did not say how big the fire was or if it would impact manufacturing at Silimed, the largest producer of silicone implants in South America. The company didn’t specify Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
